Journal: Cancer cell

Article Title: Tumor Mutation Burden and Efficacy of Nivolumab Monotherapy and in Combination With Ipilimumab in Small Cell Lung Cancer

doi: 10.1016/j.ccell.2018.04.001

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: ​ REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Rabbit anti-human PD-L1 antibody Epitomics Inc, Burlingame, CA Clone 28-8 Critical Commercial Assays Agilent/Dako PD-L1 IHC 28-8 pharmDx Agilent Technologies, Santa Clara, CA Code SK005 Allprep DNA/RNA kit Qiagen, Hilden, Germany Cat# 80234 QIAamp DNA Blood Midi Kit Qiagen, Hilden, Germany Cat# 51185 Agilent SureSelectXT reagent kit Agilent Technologies, Santa Clara, CA Cat# 5500-0133 Tapestation Agilent Technologies, Santa Clara, CA FoundationOne comprehensive genomic profile Foundation Medicine, Inc, Cambridge, MA Deposited Data VCF files containing somatic snvs per Tumor-Normal pair Sentieon’s TNsnv software European Variation Archive Accession Number: PRJEB25807 VCF files containing somatic snvs per Tumor-Normal pair Strelka software European Variation Archive Accession Number: PRJEB25808 Oligonucleotides SureSelect All Exon v5 bait Agilent Technologies, Santa Clara, CA Cat# 5190-6210 Software and Algorithms Sentieon’s somatic mutation pipeline, version 201704.01 Sentieon, Inc., Mountain View, CA The Broad Institute’s best practices for somatic mutation calling with MuTect1.3 https://software.broadinstitute.org/gatk/best-practices/ BWA (version 0.7.15) Sentieon, Inc., Mountain View, CA Sentieon’s TNsnv (reimplementation of Mutect1) Sentieon, Inc., Mountain View, CA Strelka (v1.0.15) https://sites.google.com/site/strelkasomaticvariantcaller/home snpEff (v4.1c) http://snpeff.sourceforge.net/index.html Mills’ insertions and deletions https://software.broadinstitute.org/gatk/download/bundle Other Agencourt AMPure XP beads Beckman Coulter, Indianapolis, IN Cat# {"type":"entrez-nucleotide","attrs":{"text":"A63882","term_id":"3717428","term_text":"A63882"}} A63882 Open in a separate window KEY RESOURCES TABLE This study evaluated the role of tumor mutation burden (TMB) in SCLC Efficacy of nivolumab with or without ipilimumab increases with higher TMB in SCLC The benefit of nivolumab plus ipilimumab is greatest in patients with high-TMB SCLC TMB has a potential role as a biomarker for immunotherapy across lung cancers Hellmann et al. evaluate the impact of tumor mutation burden (TMB) on the efficacy of nivolumab monotherapy or combination with ipilimumab in patients with small cell lung cancer (SCLC).

Techniques: Software, Mutagenesis